Acute lymphoblastic leukemia (ALL) results from abnormal proliferation of hematopoietic stem cells in the bone marrow (1).
ALL in adults is the result of a clonal proliferation, survival, and impaired differentiation of immature lymphocytes. These early lymphoid cells take the place of normal hematopoietic cells in the bone marrow, affecting any organ.
Pregnancy Considerations
Many chemotherapy (CTX) drugs are teratogenic.
Pediatric Considerations
ALL is the most common malignancy in children: accounts for 30% of all pediatric malignancies and 80% of pediatric leukemias (see “Acute Lymphoblastic Leukemia, Pediatric”) (1).
Geriatric Considerations
Patients aged >60 years with ALL have a 42% mortality during induction CTX. The cause of death is usually CTX-related complications or relapse. Survival is often reduced due to poor tolerance of CTX; thus, leading to dose reductions and ineffective medication delivery.
Bimodal distribution: early peak around age of 5 years, second peak at around age of 50 years (2); 80% of cases occur in children, 20% in adults.
Incidence
Prevalence
Prevalence of ALL can range from 15% to 50% and increases with age.
The pathophysiology of ALL involves the abnormal proliferation and differentiation of clonal lymphoid cells. These malignant cells proliferate and replace the bone marrow cells that would normally create red blood cells, neutrophils, and platelets; therefore, resulting in anemia, neutropenia, and thrombocytopenia
Genetics
There's more to see -- the rest of this topic is available only to subscribers.